nach oben

Clinical & Experimental Metastasis

Erschienen in:

20.12.2019 | Research Paper

Skeletal impact of 17β-estradiol in T cell-deficient mice: age-dependent bone effects and osteosarcoma formation

verfasst von: Julia N. Cheng, Jennifer B. Frye, Susan A. Whitman, Janet L. Funk

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Estrogen (E₂)-dependent ER+ breast cancer, the most common breast cancer subtype, is also the most likely to metastasize to bone and form osteolytic lesions. However, ER+ breast cancer bone metastasis human xenograft models in nude mice are rarely studied due to complexities associated with distinguishing possible tumoral vs. bone microenvironmental effects of E₂. To address this knowledge gap, we systematically examined bone effects of E₂ in developing young (4-week-old) vs. skeletally mature (15-week-old) female Foxn1^nu nude mice supplemented with commercial 60-day slow-release E₂ pellets and doses commonly used for ER+ xenograft models. E₂ pellets (0.05–0.72 mg) were implanted subcutaneously and longitudinal changes in hind limb bones (vs. age-matched controls) were determined over 6 weeks by dual-energy X-ray absorptiometry (DXA), microCT, radiographic imaging, and histology, concurrent with assessment of serum levels of E₂ and bone turnover markers. All E₂ doses tested induced significant and identical increases in bone density (BMD) and volume (BV/TV) in 4-week-old mice with high bone turnover, increasing bone mineral content (BMC) while suppressing increases in bone area (BA). E₂ supplementation, which caused dose-dependent changes in circulating E₂ that were not sustained, also led to more modest increases in BMD and BV/TV in skeletally mature 15-week-old mice. Notably, E₂-supplementation induced osteolytic osteosarcomas in a subset of mice independent of age. These results demonstrate that bone effects of E₂ supplementation should be accounted for when assessing ER+ human xenograft bone metastases models.

Redig AJ, McAllister SS (2013) Breast cancer as a systemic disease: a view of metastasis. J Intern Med 274:113–126. https://doi.org/10.1111/joim.12084 CrossRefPubMedPubMedCentral

Holen I, Speirs V, Morrissey B, Blyth K (2017) In vivo models in breast cancer research: progress, challenges and future directions. Dis Model Mech 10:359–371. https://doi.org/10.1242/dmm.028274 CrossRefPubMedPubMedCentral

Wright LE, Ottewell PD, Rucci N et al (2016) Murine models of breast cancer bone metastasis. BoneKEy Rep 5:804. https://doi.org/10.1038/bonekey.2016.31 CrossRefPubMedPubMedCentral

Özdemir BC, Sflomos G, Brisken C (2018) The challenges of modeling hormone receptor-positive breast cancer in mice. Endocr Relat Cancer 25:R319–R330. https://doi.org/10.1530/ERC-18-0063 CrossRefPubMed

Morgan RA (2012) Human tumor xenografts: the good, the bad, and the ugly. Mol Ther 20:882. https://doi.org/10.1038/MT.2012.73 CrossRefPubMedPubMedCentral

Nilsson ME, Vandenput L, Tivesten Å et al (2015) Measurement of a comprehensive sex steroid profile in rodent serum by high-sensitive gas chromatography-tandem mass spectrometry. Endocrinology 156:2492–2502. https://doi.org/10.1210/en.2014-1890 CrossRefPubMed

Zhao H, Zhou L, Shangguan AJ, Bulun SE (2016) Aromatase expression and regulation in breast and endometrial cancer. J Mol Endocrinol 57:R19–33. https://doi.org/10.1530/JME-15-0310 CrossRefPubMedPubMedCentral

Sjögren K, Lagerquist M, Moverare-Skrtic S et al (2009) Elevated aromatase expression in osteoblasts leads to increased bone mass without systemic adverse effects. J Bone Miner Res 24:1263–1270. https://doi.org/10.1359/jbmr.090208 CrossRefPubMed

Köpf-Maier P, Mboneko VF (1990) Anomalies in the hormonal status of athymic nude mice. J Cancer Res Clin Oncol 116:229–231. https://doi.org/10.1007/BF01612895 CrossRefPubMed

10.

Jordan VC, Gottardis MM, Robinson SP, Friedl A (1989) Immune-deficient animals to study “hormone-dependent” breast and endometrial cancer. J Steroid Biochem 34:169–176CrossRef

11.

Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ CK (2018) SEER Cancer Statistics Review, 1975–2015, National Cancer Institute. In: SEER Cancer Stat. Rev. 1975–2015, Natl. Cancer Institute. https://seer.cancer.gov/csr/1975_2015/. Accessed 12 Apr 2018

12.

Osborne CK, Hobbs K, Clark GM (1985) Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res 45:584–590PubMed

13.

Shafie SM, Liotta LA (1980) Formation of metastasis by human breast carcinoma cells (MCF-7) in nude mice. Cancer Lett 11:81–87CrossRef

14.

Gottardis MM, Robinson SP, Jordan VC (1988) Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem 30:311–314CrossRef

15.

Soni A, Ren Z, Hameed O et al (2015) Breast cancer subtypes predispose the site of distant metastases. Am J Clin Pathol 143:471–478. https://doi.org/10.1309/AJCPYO5FSV3UPEXS CrossRefPubMed

16.

Han HH, Lee SH, Kim BG et al (2016) Estrogen receptor status predicts late-onset skeletal recurrence in breast cancer patients. Medicine (Baltimore) 95:e2909. https://doi.org/10.1097/MD.0000000000002909 CrossRef

17.

Winding B, Misander H, Høegh-Andersen P et al (2003) Estradiol enhances osteolytic lesions in mice inoculated with human estrogen receptor-negative MDA-231 breast cancer cells in vivo. Breast Cancer Res Treat 78:205–216. https://doi.org/10.1016/j.steroids.2017.10.010 CrossRefPubMed

18.

Cohen DJ, Patel V, Verma A, Schwartz Z (2019) Effect of 17β-estradiol on estrogen receptor negative breast cancer cells in an osteolytic mouse model. Steroids 142:28–33. https://doi.org/10.1016/J.STEROIDS.2017.10.010 CrossRefPubMed

19.

Ottewell PD, Wang N, Brown HK et al (2015) OPG-Fc inhibits ovariectomy-induced growth of disseminated breast cancer cells in bone. Int J Cancer 137:968–977. https://doi.org/10.1002/ijc.29439 CrossRefPubMed

20.

Wright LE, Harhash AA, Kozlow WM et al (2017) Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo. Oncotarget 8:8406–8419. https://doi.org/10.18632/oncotarget.14139 CrossRefPubMed

21.

Rabbani SA, Khalili P, Arakelian A et al (2005) Regulation of parathyroid hormone-related peptide by estradiol: effect on tumor growth and metastasis in vitro and in vivo. Endocrinology 146:2885–2894. https://doi.org/10.1210/en.2005-0062 CrossRefPubMed

22.

Ottewell PD, Wang N, Brown HK et al (2014) Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo. Clin Cancer Res 20:2922–2932. https://doi.org/10.1158/1078-0432.CCR-13-1246 CrossRefPubMedPubMedCentral

23.

Ogba N, Manning NG, Bliesner BS et al (2014) Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells. Breast Cancer Res 16:489. https://doi.org/10.1186/s13058-014-0489-4 CrossRefPubMedPubMedCentral

24.

Canon J, Bryant R, Roudier M et al (2012) RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model. Breast Cancer Res Treat 135:771–780. https://doi.org/10.1007/s10549-012-2222-2 CrossRefPubMed

25.

Holen I, Walker M, Nutter F et al (2015) Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo. Clin Exp Metastasis 33:211–224. https://doi.org/10.1007/s10585-015-9770-x CrossRefPubMed

26.

Ganapathy V, Banach-Petrosky W, Xie W et al (2012) Luminal breast cancer metastasis is dependent on estrogen signaling. Clin Exp Metastasis 29:493–509. https://doi.org/10.1007/s10585-012-9466-4 CrossRefPubMed

27.

Johnson RW, Finger EC, Olcina MM et al (2016) Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow. Nat Cell Biol 18:1078–1089. https://doi.org/10.1038/ncb3408 CrossRefPubMedPubMedCentral

28.

Sowder ME, Johnson RW (2018) Enrichment and detection of bone disseminated tumor cells in models of low tumor burden. Sci Rep 8:14299. https://doi.org/10.1038/s41598-018-32653-2 CrossRefPubMedPubMedCentral

29.

Li Y, Zhang H, Zhao Y et al (2019) A mandatory role of nuclear PAK4-LIFR axis in breast-to-bone metastasis of ERα-positive breast cancer cells. Oncogene 38:808–821. https://doi.org/10.1038/s41388-018-0456-0 CrossRefPubMed

30.

Thomas RJ, Guise TA, Yin JJ et al (1999) Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140:4451–4458. https://doi.org/10.1210/endo.140.10.7037 CrossRefPubMed

31.

Willinghamm MD, Brodt MD, Lee KL et al (2010) Age-related changes in bone structure and strength in female and male BALB/c mice. Calcif Tissue Int 86:470–483. https://doi.org/10.1007/s00223-010-9359-y CrossRefPubMed

32.

Glatt V, Canalis E, Stadmeyer L, Bouxsein ML (2007) Age-related changes in trabecular architecture differ in female and male C57BL/6J mice. J Bone Miner Res 22:1197–1207. https://doi.org/10.1359/jbmr.070507 CrossRefPubMed

33.

Modder UIL, Riggs BL, Spelsberg TC et al (2004) Dose-response of estrogen on bone versus the uterus in ovariectomized mice. Eur J Endocrinol 151:503–510CrossRef

34.

Urist MR, Budy AM, McLean FC (1950) Endosteal-bone formation in estrogen-treated mice. J Bone Joint Surg 32A:143–162 CrossRef

35.

Turner CH, Hsieh Y-F, Müller R et al (2000) Genetic regulation of cortical and trabecular bone strength and microstructure in inbred strains of mice. J Bone Miner Res 15:1126–1131. https://doi.org/10.1359/jbmr.2000.15.6.1126 CrossRefPubMed

36.

Bouxsein ML, Myers KS, Shultz KL et al (2005) Ovariectomy-induced bone loss varies among inbred strains of mice. J Bone Miner Res 20:1085–1092. https://doi.org/10.1359/JBMR.050307 CrossRefPubMed

37.

Cenci S, Weitzmann MN, Roggia C et al (2000) Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Investig 106:1229–1237. https://doi.org/10.1172/JCI11066 CrossRefPubMed

38.

Haisenleder DJ, Schoenfelder AH, Marcinko ES et al (2011) Estimation of estradiol in mouse serum samples: evaluation of commercial estradiol immunoassays. Endocrinology 152:4443–4447. https://doi.org/10.1210/en.2011-1501 CrossRefPubMedPubMedCentral

39.

Wright LE, Frye JB, Lukefahr AL et al (2013) Curcuminoids block TGF-β signaling in human breast cancer cells and limit osteolysis in a murine model of breast cancer bone metastasis. J Nat Prod 76:316–321. https://doi.org/10.1021/np300663v CrossRefPubMed

40.

Dempster DW, Compston JE, Drezner MK et al (2013) Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 28:2–17. https://doi.org/10.1002/jbmr.1805 CrossRefPubMedPubMedCentral

41.

Streicher C, Heyny A, Andrukhova O et al (2017) Estrogen regulates bone turnover by targeting rankl expression in bone lining cells. Sci Rep 7:6460. https://doi.org/10.1038/s41598-017-06614-0 CrossRefPubMedPubMedCentral

42.

Machado I, Navarro S, Picci P, Llombart-Bosch A (2016) The utility of SATB2 immunohistochemical expression in distinguishing between osteosarcomas and their malignant bone tumor mimickers, such as Ewing sarcomas and chondrosarcomas. Pathol-Res Pract 212:811–816. https://doi.org/10.1016/J.PRP.2016.06.012 CrossRefPubMed

43.

Conner JR, Hornick JL (2013) SATB2 is a novel marker of osteoblastic differentiation in bone and soft tissue tumours. Histopathology 63:36–49. https://doi.org/10.1111/his.12138 CrossRefPubMed

44.

Braidman IP, Hainey L, Batra G et al (2001) Localization of estrogen receptor β protein expression in adult human bone. J Bone Miner Res 16:214–220. https://doi.org/10.1359/jbmr.2001.16.2.214 CrossRefPubMed

45.

Mbalaviele G, Dunstan CR, Sasaki A et al (1996) E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. Cancer Res 56:4063–4070PubMed

46.

Guise TA, Yin JJ, Taylor SD et al (1996) Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Investig 98:1544–1549. https://doi.org/10.1172/JCI118947 CrossRefPubMed

47.

Kang Y, Siegel PM, Shu W et al (2003) A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3:537–549. https://doi.org/10.1016/S1535-6108(03)00132-6 CrossRefPubMed

48.

Odgaard A, Gundersen HJ (1993) Quantification of connectivity in cancellous bone, with special emphasis on 3-D reconstructions. Bone 14:173–182CrossRef

49.

Salmon PL, Ohlsson C, Shefelbine SJ, Doube M (2015) Structure model index does not measure rods and plates in trabecular bone. Front Endocrinol (Lausanne) 6:162. https://doi.org/10.3389/fendo.2015.00162 CrossRef

50.

Hildebrand T, Rüegsegger P (1997) Quantification of bone microarchitecture with the structure model index. Comput Methods Biomech Biomed Engin 1:15–23. https://doi.org/10.1080/01495739708936692 CrossRefPubMed

51.

Bouxsein ML, Boyd SK, Christiansen BA et al (2010) Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 25:1468–1486. https://doi.org/10.1002/jbmr.141 CrossRefPubMed

52.

Connell NT, Shurin SB, Schiffman F (2018) The spleen and its disorders. In: Hoffman R, Benz EJ, Silberstein LE et al (eds) Hematology: basic principles and practice, 7th edn. Elsevier, Philadelphia, PA, pp 2313–2327CrossRef

53.

Pearse G, Frith J, Randall KJ, Klinowska T (2009) Urinary retention and cystitis associated with subcutaneous estradiol pellets in female nude mice. Toxicol Pathol 37:227–234. https://doi.org/10.1177/0192623308329281 CrossRefPubMed

54.

Gakhar G, Wight-Carter M, Andrews G et al (2009) Hydronephrosis and urine retention in estrogen-implanted athymic nude mice. Vet Pathol 46:505–508. https://doi.org/10.1354/vp.08-VP-0180-N-BC CrossRefPubMed

55.

Ingberg E, Theodorsson A, Theodorsson E, Strom JO (2012) Methods for long-term 17β-estradiol administration to mice. Gen Comp Endocrinol 175:188–193. https://doi.org/10.1016/J.YGCEN.2011.11.014 CrossRefPubMed

56.

Wang F-S, Wu R-W, Lain W-S et al (2018) Sclerostin vaccination mitigates estrogen deficiency induction of bone mass loss and microstructure deterioration. Bone 112:24–34. https://doi.org/10.1016/j.bone.2018.04.007 CrossRefPubMed

57.

Panwar P, Xue L, Søe K et al (2017) An ectosteric inhibitor of cathepsin k inhibits bone resorption in ovariectomized mice. J Bone Miner Res 32:2415–2430. https://doi.org/10.1002/jbmr.3227 CrossRefPubMed

58.

Hawse JR, Pitel KS, Cicek M et al (2014) TGFβ inducible early gene-1 plays an important role in mediating estrogen signaling in the skeleton. J Bone Miner Res 29:1206–1216. https://doi.org/10.1002/jbmr.2142 CrossRefPubMedPubMedCentral

59.

Ballanti P, Minisola S, Pacitti MT et al (1997) Tartrate-resistant acid phosphate activity as osteoclastic marker: sensitivity of cytochemical assessment and serum assay in comparison with standardized osteoclast histomorphometry. Osteoporos Int 7:39–43. https://doi.org/10.1007/BF01623458 CrossRefPubMed

60.

O’Connell KE, Mikkola AM, Stepanek AM et al (2015) Practical murine hematopathology: a comparative review and implications for research. Comp Med 65:96PubMedPubMedCentral

61.

Erlandsson M, Jonsson C, Lindberg M et al (2002) Raloxifene- and estradiol-mediated effects on uterus, bone and B lymphocytes in mice. J Endocrinol 175:319–327. https://doi.org/10.1677/joe.0.1750319 CrossRefPubMed

62.

Erlandsson MC, Islander U, Moverare S et al (2005) Estrogenic agonism and antagonism of the soy isoflavone genistein in uterus, bone and lymphopoiesis in mice. APMIS 113:317–323. https://doi.org/10.1111/j.1600-0463.2005.apm_113502.x CrossRefPubMed

63.

Medina KL, Strasser A, Kincade PW (2000) Estrogen influences the differentiation, proliferation, and survival of early B-lineage precursors. Blood 95:2059–2067CrossRef

64.

Strauss JF, Barbieri RL, Yen SSC (2019) Yen and Jaffe’s reproductive endocrinology: physiology, pathophysiology, and clinical management, 8th edn. Elsevier, Philadelphia, PA

65.

Gérard C, Gallez A, Dubois C et al (2017) Accurate control of 17β-estradiol long-term release increases reliability and reproducibility of preclinical animal studies. J Mammary Gland Biol Neoplasia 22:1–11. https://doi.org/10.1007/s10911-016-9368-1 CrossRefPubMed

66.

Haynes K, Tyner C, Williams PD (2013) Repiphysis prosthesis for limb preservation in pediatric patients with bone cancer: a literature review. Orthop Nurs 32:81–86. https://doi.org/10.1097/NOR.0b013e3182879bbb CrossRefPubMed

67.

Chen Y, Yu X, Xu S et al (2016) Impacts of tumor location, nature and bone destruction of extremity osteosarcoma on selection of limb salvage operative procedure. Orthop Surg 8:139–149. https://doi.org/10.1111/os.12237 CrossRefPubMedPubMedCentral

68.

Highman B, Roth SI, Greenman DL (1981) Osseous changes and osteosarcomas in mice continuously fed diets containing diethylstilbestrol or 17β-estradiol. J Natl Cancer Inst 67:653–662. https://doi.org/10.1093/jnci/67.3.653 CrossRefPubMed

69.

Vahle JL, Long GG, Sandusky G et al (2004) Bone neoplasms in f344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 32:426–438. https://doi.org/10.1080/01926230490462138 CrossRef

70.

Vahle JL, Sato M, Long GG et al (2002) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safety. Toxicol Pathol 30:312–321. https://doi.org/10.1080/01926230252929882 CrossRefPubMed

Titel: Skeletal impact of 17β-estradiol in T cell-deficient mice: age-dependent bone effects and osteosarcoma formation
verfasst von: Julia N. Cheng
Jennifer B. Frye
Susan A. Whitman
Janet L. Funk
Publikationsdatum: 20.12.2019
Verlag: Springer Netherlands
Erschienen in: Clinical & Experimental Metastasis / Ausgabe 2/2020
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-019-10012-3

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Skeletal impact of 17β-estradiol in T cell-deficient mice: age-dependent bone effects and osteosarcoma formation

Abstract

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Poor perfusion of the microvasculature in peritoneal metastases of ovarian cancer

The utility of the “Glowing Head” mouse for breast cancer metastasis research

Development of a novel murine model of lymphatic metastasis

Suppression of migration, invasion, and metastasis of cisplatin-resistant head and neck squamous cell carcinoma through IKKβ inhibition

A novel RNA sequencing-based risk score model to predict papillary thyroid carcinoma recurrence

Upfront radiosurgery plus targeted agents followed by active brain control using radiosurgery delays neurological death in non-small cell lung cancer with brain metastasis

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie